Tags

Type your tag names separated by a space and hit enter

Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
Expert Opin Drug Saf. 2016 Jan; 15(1):117-29.EO

Abstract

INTRODUCTION

As a chronic disease, allergic rhinitis (AR) requires regular use of allergy medications for the effective management of symptoms. It is therefore imperative that AR treatments not only provide adequate symptom control but are also well tolerated.

AREAS COVERED

MP29-02 (Dymista, Meda, Solna, Sweden) is the first new class of AR medication (WHO ATC R01AD58) since the introduction of intranasal corticosteroids (INS) almost 50 years ago. It is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate delivered in a single spray. Here we review all the safety information relevant to MP29-02, from the initial phase I bioavailability and disposition data, to the phase III 14-day and 52-week data and finally to phase IV safety data collected during MP29-02 use in routine clinical practice.

EXPERT OPINION

MP29-02 is the first real therapeutic advance in AR since the introduction of INS and has the potential to change the way this disease is managed, simplifying AR treatment regimens to a single puff in each nostril twice a day. Patients will benefit from superior symptom relief MP29-02 compared to INS with the added assurance that the safety of MP29-02 has been confirmed in the short term and long term as well as in real life.

Authors+Show Affiliations

a Department of Otorhinolaryngology , Zentrum für Rhinologie und Allergologie , An den Quellen 10 D-65183 , Wiesbaden , Germany.b Department of Pneumology , University of Montpellier - Hopital Arnaud de Villeneuve , Montpellier , France.c General Practice Airways Group Professor of Primary Care Respiratory Medicine, Department of General Practice and Primary Care, Foresterhill Health Centre , University of Aberdeen , Westburn Road, Aberdeen AB25 2AY , UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26581312

Citation

Klimek, Ludger, et al. "Safety Evaluation of MP29-02 (a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) for Allergic Rhinitis." Expert Opinion On Drug Safety, vol. 15, no. 1, 2016, pp. 117-29.
Klimek L, Bousquet J, Price D. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Expert Opin Drug Saf. 2016;15(1):117-29.
Klimek, L., Bousquet, J., & Price, D. (2016). Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Expert Opinion On Drug Safety, 15(1), 117-29. https://doi.org/10.1517/14740338.2016.1122755
Klimek L, Bousquet J, Price D. Safety Evaluation of MP29-02 (a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) for Allergic Rhinitis. Expert Opin Drug Saf. 2016;15(1):117-29. PubMed PMID: 26581312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. AU - Klimek,Ludger, AU - Bousquet,Jean, AU - Price,David, Y1 - 2015/12/23/ PY - 2015/11/20/entrez PY - 2015/11/20/pubmed PY - 2016/9/16/medline KW - Dymista KW - MP29-02 KW - allergic rhinitis KW - azelastine KW - fluticasone propionate KW - safety SP - 117 EP - 29 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 15 IS - 1 N2 - INTRODUCTION: As a chronic disease, allergic rhinitis (AR) requires regular use of allergy medications for the effective management of symptoms. It is therefore imperative that AR treatments not only provide adequate symptom control but are also well tolerated. AREAS COVERED: MP29-02 (Dymista, Meda, Solna, Sweden) is the first new class of AR medication (WHO ATC R01AD58) since the introduction of intranasal corticosteroids (INS) almost 50 years ago. It is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate delivered in a single spray. Here we review all the safety information relevant to MP29-02, from the initial phase I bioavailability and disposition data, to the phase III 14-day and 52-week data and finally to phase IV safety data collected during MP29-02 use in routine clinical practice. EXPERT OPINION: MP29-02 is the first real therapeutic advance in AR since the introduction of INS and has the potential to change the way this disease is managed, simplifying AR treatment regimens to a single puff in each nostril twice a day. Patients will benefit from superior symptom relief MP29-02 compared to INS with the added assurance that the safety of MP29-02 has been confirmed in the short term and long term as well as in real life. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/26581312/Safety_evaluation_of_MP29_02__a_novel_intranasal_formulation_of_azelastine_hydrochloride_and_fluticasone_propionate__for_allergic_rhinitis_ L2 - https://www.tandfonline.com/doi/full/10.1517/14740338.2016.1122755 DB - PRIME DP - Unbound Medicine ER -